NovoCure Ltd (MEX:NVCR)
MXN 275.39 0 (0%) Market Cap: 37.39 Bil Enterprise Value: 31.76 Bil PE Ratio: 0 PB Ratio: 5.23 GF Score: 69/100

Novocure Ltd at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2022 / 12:30PM GMT
Release Date Price: MXN1777.59
Gavin Scott
JPMorgan Chase & Co, Research Division - Analyst

Good morning, and welcome to day 2 of the 40th Annual JPMorgan Healthcare Conference. My name is Gavin Scott, and I'm a biotech analyst here at JPMorgan. This morning, it's my pleasure to introduce Novocure and the company's Executive Chairman, Bill Doyle. Please note that we will be going straight into a Q&A session following the presentation. So please feel free to use to ask a question button on your screen or e-mail me directly. With that, I'll leave it to you, Mr. Doyle.

William F. Doyle
NovoCure Limited - Executive Chairman

Okay. Good morning, everyone. Again, I'll add my welcome to Gavin to the first presentation of the morning. Just mechanics here, I believe you have the presentation on your screen, but you need to advance your own slides. So I'm going to reference the page numbers as I move forward, but you need to move the slides yourself. So first, I have to mention that I'll be making forward-looking statements. If anyone wants to see the full statement. It's available on our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot